Displaying 139 (all) recruiting clinical trials.
-
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
The purpose of the study is to determine the overall response rates as well as safety and tolerability of olaparib in subjects with recurrent/progressive ... -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
The purpose of the study is to evaluate the biological activity of systemic therapies in people with Neurofibromatosis type 2 (NF2) related tumors. Tumor types ... -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
The purpose of the study is to determine if M3814 in combination with radiation therapy and avelumab is safe and tolerable in patients with advanced ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ... -
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ... -
A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)
The purpose of the study is to determine the safety and efficacy of Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) for people who have muscle-invasive bladder cancer ... -
Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC
The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With ... -
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that ... -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ... -
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
The purpose of the study is to determine the safety and tolerability of investigational treatment combinations with or without pembrolizumab or pembrolizumab alone for the ...